Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies , pressing for new ...
Deep Track, a Greenwich, Ct., investment management company that holds 13.5% of Dynavax's stock, pointed its finger at ...
Good day, ladies and gentlemen, and welcome to the Dynavax Technologies fourth quarter and full year 2024 financial results ...
Research analysts at William Blair reduced their Q1 2025 earnings per share estimates for Dynavax Technologies in a report ...
Citizens JMP raised the firm’s price target on Dynavax (DVAX) to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported ...
After privately vying for a change to Dynavax’s corporate strategy for months, life sciences investment firm Deep Track ...
Dynavax Technologies (NASDAQ:DVAX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by William Blair in a note issued to investors on Friday,RTT News reports. William Blair also issued ...
Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement ...
4d
Dynavax Technologies Corp (DVAX) reports record revenue for Heplisav-B, advances in vaccine programs, and strategic financial positioning despite rising R&D costs.
Dynavax expects HEPLISAV-B product revenue in 2025 to range between $305 million and $325 million, representing a 17% year-over-year growth at the midpoint. The company anticipates achieving key ...
JMP Securities analyst Jason Butler reiterated a Buy rating on Dynavax (DVAX – Research Report) today and set a price target of $33.00. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback